Dr. Mengyu Lu

Dr. Lu has advised the following corporate transactions*:

Listings in Hong Kong / U.S.

Healthcare

• Duality Biotherapeutics, Fangzhou Inc, ImmuneOnco Biopharmaceuticals, Sichuan Kelun-Biotech, ADICON, Yunkang Group, Jiangsu Recbio, Arrail Group, CANbridge Pharmaceuticals, Beijing Airdoc, Clover Biopharmaceuticals, Keymed Biosciences, Zhaoke Ophthalmology, Suzhou Basecare, MicroPort CardioFlow Medtech, Ocumension Therapeutics, Kangji Medical, Alphamab Oncology, Shanghai Henlius, Viva Biotech, CanSino Biologics, Ascletis Pharma

TMT & Auto

• iMotion, TUHU, Jinxin Technology, ZKH Group, ZX Inc., 360 DigiTech, STAR CM, Li Auto, Joy Spreader, Strawbear Entertainment, BabyTree Group

Consumer & Education

• Super Hi International, Nayuki Holdings, Yum China, Haidilao International, Xiao Nan Guo, China Chunlai Education, China YuHua Education

Industrial, Energy & Natural Resources

• Rizhao Port, Shandong Gold, China Railway Signal & Communication, Qinhuangdao Port, Sinopec Engineering, NVC Lighting

Financial Institutions

• Noah Holdings, Bank of Jiujiang, Guangzhou Rural Commercial Bank, China Huarong Asset Management

SPAC & De-SPAC

• Vision Deal, ZG Group

Follow-on Offerings & Pre-IPO Financings

• ImmuneOnco Biopharmaceuticals, Sichuan Kelun-Biotech, iMotion, Will Semiconductor, NIO, Clover Biopharmaceuticals, Haidilao, AlphaMab Oncology, Joy Spreader, Viva Biotech, Zhaoke Ophthalmology, Microport Cardioflow, China Cinda, China Galaxy Securities, Datang International Power Generation

Private Equity, M&A & Other Corporate Matters

• ZG Group (HKEX: 6676) on its successful de-SPAC transaction involving a business combination with Aquila Acquisition Corporation. ZG Group commenced trading on the Hong Kong Stock Excahnge on March 10, 2025. The company has a negotiated value of HK$10 billion and has secured a total of HK$548 million in PIPE investment and permitted equity financing. This transaction marks the company with the highest value since the introduction of the SPAC listing regime in Hong Kong on January 1, 2022
• Edding Group Company Limited, an integrated biopharmaceutical company, in connection with a proposed merger and reverse takeover with Genor Biopharma Holdings Limited, a Hong Kong-listed biopharmaceutical company under Chapter 18A. The deal represents the first ever reverse takeover relating to a Chapter 18A listed company. This transaction was named “Deals of the Year 2024” by China Business Law Journal
• Suzhou Ribo Life Science Co., Ltd. (Ribo), a clinical stage company developing innovative RNAi technologies and oligonucleotide therapeutics, on the successful completion of its $40 million Series E1 financing
• Carlyle on its US$210 million investment, as a cornerstone investor, in connection with HUTCHMED’s primary listing on the Hong Kong Stock Exchange. HUTCHMED has primary listings on NASDAQ and on AIM
• Bain Capital in its US$200 million strategic investment in Newlinks Technology Limited, a fast-growing online energy technology platform in China
• Airdoc, a global market leader and pioneer in providing AI-empowered retina-based early detection, diagnosis and health risk assessment solutions, in the successful completion of its Series D financing. Lilly Asia Ventures, Lake Bleu Capital and OrbiMed jointly participated in this investment
• Clover Biopharmaceuticals, a global clinical-stage biotechnology company developing transformative biologics as vaccines and therapeutics for the world’s most debilitating diseases, on the successful completion of an oversubscribed US$230 million Series C financing. The financing round was co-led by GL Ventures and Temasek, with participation from Oceanpine Capital, OrbiMed and existing investor Delos Capital
• EDDA Healthcare and Technology Holding Limited, a pioneer in the field of intelligent robotic solutions for precision surgery, on the successful completion of a US$150 million financing round. Softbank Vision Fund 2 led this investment round with participation from OrbiMed and 3W Fund 
• Ocumension Therapeutics (HKSE: 1477) in connection with its subscription of shares in EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT). Upon completion of the transaction, Ocumension holds approximately 16.6% of the enlarged total outstanding shares of EyePoint. Ocumension Therapeutics is an ophthalmic pharmaceutical platform company
• Advaccine in a collaboration and license agreement with INOVIO for COVID-19 DNA vaccine candidate INO-4800. Advaccine is an emerging biotech company with next-generation technology in vaccines, both preventive and therapeutic
• BabyTree Group, a leading online parenting services platform in China, on a strategic investment by Alibaba Group
• Xiwang Foodstuffs Co., Ltd., in its US$730 million acquisition of Kerr Investment Holding Corp / Iovate Health Sciences International, Inc
• CICC, as the sole financial advisor to CGN Mining Company Limited, in relation to CGN Mining’s acquisition of 19.99% equity interest in the TSX-listed Fission Uranium Corp. for CA$82 million (equivalent to approximately HK$450 million)

*Including matters prior to her rejoining Kirkland & Ellis

Sidley Austin, 2015–2021

Kirkland & Ellis, 2011–2015

Freshfields Bruckhaus Deringer, 2008–2010